Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Interferon lambda 4 impacts the genetic diversity of hepatitis C virus.

Ansari MA, Aranday-Cortes E, Ip CL, da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM; STOP-HCV Consortium, Ball J, Barnes E, Burgess G, Cooke G, Dillon J, Foster G, Gore C, Guha N, Halford R, Holmes C, Hudson E, Hutchinson S, Irving W, Khakoo S, Klenerman P, Martin N, Mbisa T, McKeating J, McLauchlan J, Miners A, Murray A, Shaw P, Simmonds P, Smith S, Spencer C, Thomson E, Troke P, Vickerman P, Zitzmann N, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, McLauchlan J, Pedergnana V.

Elife. 2019 Sep 3;8. pii: e42463. doi: 10.7554/eLife.42463.

2.

Bacterial flagellin promotes viral entry via an NF-kB and Toll Like Receptor 5 dependent pathway.

Benedikz EK, Bailey D, Cook CNL, Gonçalves-Carneiro D, Buckner MMC, Blair JMA, Wells TJ, Fletcher NF, Goodall M, Flores-Langarica A, Kingsley RA, Madsen J, Teeling J, Johnston SL, MacLennan CA, Balfe P, Henderson IR, Piddock LJV, Cunningham AF, McKeating JA.

Sci Rep. 2019 May 27;9(1):7903. doi: 10.1038/s41598-019-44263-7.

3.

A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis.

Wing PA, Davenne T, Wettengel J, Lai AG, Zhuang X, Chakraborty A, D'Arienzo V, Kramer C, Ko C, Harris JM, Schreiner S, Higgs M, Roessler S, Parish JL, Protzer U, Balfe P, Rehwinkel J, McKeating JA.

Life Sci Alliance. 2019 Mar 27;2(2). pii: e201900355. doi: 10.26508/lsa.201900355. Print 2019 Apr.

4.

The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication.

Zhuang X, Magri A, Hill M, Lai AG, Kumar A, Rambhatla SB, Donald CL, Lopez-Clavijo AF, Rudge S, Pinnick K, Chang WH, Wing PAC, Brown R, Qin X, Simmonds P, Baumert TF, Ray D, Loudon A, Balfe P, Wakelam M, Butterworth S, Kohl A, Jopling CL, Zitzmann N, McKeating JA.

Nat Commun. 2019 Jan 22;10(1):377. doi: 10.1038/s41467-019-08299-7.

5.

Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure.

Lim TR, Hazlehurst JM, Oprescu AI, Armstrong MJ, Abdullah SF, Davies NP, Flintham R, Balfe P, Mutimer DJ, McKeating JA, Tomlinson JW.

Clin Endocrinol (Oxf). 2019 Mar;90(3):440-448. doi: 10.1111/cen.13924. Epub 2019 Jan 17.

6.

Glucose and glutamine availability regulate HepG2 transcriptional responses to low oxygen.

Lai AG, Forde D, Chang WH, Yuan F, Zhuang X, Orbegozo Rubio C, Song CX, McKeating JA.

Wellcome Open Res. 2018 Sep 26;3:126. doi: 10.12688/wellcomeopenres.14839.1. eCollection 2018.

7.

Daytime variation in hepatitis C virus replication kinetics following liver transplant.

Zhuang X, Lai AG, McKeating JA, Rowe I, Balfe P.

Version 2. Wellcome Open Res. 2018 Sep 20 [revised 2018 Jan 1];3:96. doi: 10.12688/wellcomeopenres.14696.2. eCollection 2018.

8.

Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.

McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC.

Gastroenterology. 2019 Jan;156(2):384-399. doi: 10.1053/j.gastro.2018.07.058. Epub 2018 Sep 27. Review.

9.

Metallo supramolecular cylinders inhibit HIV-1 TAR-TAT complex formation and viral replication in cellulo.

Cardo L, Nawroth I, Cail PJ, McKeating JA, Hannon MJ.

Sci Rep. 2018 Sep 6;8(1):13342. doi: 10.1038/s41598-018-31513-3.

10.

Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.

Ko C, Chakraborty A, Chou WM, Hasreiter J, Wettengel JM, Stadler D, Bester R, Asen T, Zhang K, Wisskirchen K, McKeating JA, Ryu WS, Protzer U.

J Hepatol. 2018 Dec;69(6):1231-1241. doi: 10.1016/j.jhep.2018.08.012. Epub 2018 Aug 22.

PMID:
30142426
11.

Correction to 'Viral hepatitis and liver cancer'.

Ringelhan M, McKeating JA, Protzer U.

Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737). pii: 20170339. doi: 10.1098/rstb.2017.0339. No abstract available.

12.

A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.

Grove J, Hu K, Farquhar MJ, Goodall M, Walker L, Jamshad M, Drummer HE, Bill RM, Balfe P, McKeating JA.

Wellcome Open Res. 2017 Sep 7;2:82. doi: 10.12688/wellcomeopenres.12058.1. eCollection 2017.

13.

Interplay between circadian clock and viral infection.

Zhuang X, Rambhatla SB, Lai AG, McKeating JA.

J Mol Med (Berl). 2017 Dec;95(12):1283-1289. doi: 10.1007/s00109-017-1592-7. Epub 2017 Sep 30. Review.

14.

Viral hepatitis and liver cancer.

Ringelhan M, McKeating JA, Protzer U.

Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732). pii: 20160274. doi: 10.1098/rstb.2016.0274. Review. Erratum in: Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):.

15.

Glucocorticoids promote Von Hippel Lindau degradation and Hif-1α stabilization.

Vettori A, Greenald D, Wilson GK, Peron M, Facchinello N, Markham E, Sinnakaruppan M, Matthews LC, McKeating JA, Argenton F, van Eeden FJM.

Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):9948-9953. doi: 10.1073/pnas.1705338114. Epub 2017 Aug 29.

16.

Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.

Farquhar MJ, Humphreys IS, Rudge SA, Wilson GK, Bhattacharya B, Ciaccia M, Hu K, Zhang Q, Mailly L, Reynolds GM, Ashcroft M, Balfe P, Baumert TF, Roessler S, Wakelam MJO, McKeating JA.

J Hepatol. 2017 May;66(5):919-929. doi: 10.1016/j.jhep.2017.01.009. Epub 2017 Jan 23.

PMID:
28126468
17.

N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection.

Appelman MD, Chakraborty A, Protzer U, McKeating JA, van de Graaf SF.

PLoS One. 2017 Jan 26;12(1):e0170419. doi: 10.1371/journal.pone.0170419. eCollection 2017.

18.

The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis.

Gonçalves-Carneiro D, McKeating JA, Bailey D.

J Virol. 2017 Mar 13;91(7). pii: e02255-16. doi: 10.1128/JVI.02255-16. Print 2017 Apr 1.

19.

TNF superfamily members promote hepatitis C virus entry via an NF-κB and myosin light chain kinase dependent pathway.

Fletcher NF, Clark AR, Balfe P, McKeating JA.

J Gen Virol. 2017 Mar;98(3):405-412. doi: 10.1099/jgv.0.000689. Epub 2017 Apr 1.

20.

Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes.

Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF.

Cell Rep. 2016 Oct 25;17(5):1357-1368. doi: 10.1016/j.celrep.2016.09.084.

21.

High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.

Hedegaard DL, Tully DC, Rowe IA, Reynolds GM, Bean DJ, Hu K, Davis C, Wilhelm A, Ogilvie CB, Power KA, Tarr AW, Kelly D, Allen TM, Balfe P, McKeating JA.

J Hepatol. 2017 Jan;66(1):28-38. doi: 10.1016/j.jhep.2016.07.048. Epub 2016 Aug 13.

22.

A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.

Zhang YH, Zhao Y, Rajapaksa US, Lawrence TM, Peng YC, Liu J, Xu K, Hu K, Qin L, Liu N, Sun H, Yan HP, Repapi E, Rowland-Jones S, Thimme R, McKeating JA, Dong T.

PLoS One. 2016 Jul 25;11(7):e0158037. doi: 10.1371/journal.pone.0158037. eCollection 2016.

23.

Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients.

Tully DC, Hjerrild S, Leutscher PD, Renvillard SG, Ogilvie CB, Bean DJ, Videbech P, Allen TM, McKeating JA, Fletcher NF.

Liver Int. 2016 Oct;36(10):1418-24. doi: 10.1111/liv.13134. Epub 2016 Apr 26.

24.

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.

Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P.

Hepatology. 2016 Apr;63(4):1120-34. doi: 10.1002/hep.28428. Epub 2016 Feb 22.

PMID:
26710081
25.

Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors.

Meredith LW, Hu K, Cheng X, Howard CR, Baumert TF, Balfe P, van de Graaf KF, Protzer U, McKeating JA.

J Gen Virol. 2016 Jan;97(1):121-7. doi: 10.1099/jgv.0.000317. Epub 2015 Oct 16.

26.

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.

Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ.

Liver Transpl. 2016 Mar;22(3):287-97. doi: 10.1002/lt.24349.

27.

Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.

Mathiesen CK, Prentoe J, Meredith LW, Jensen TB, Krarup H, McKeating JA, Gottwein JM, Bukh J.

J Virol. 2015 Aug;89(15):7758-75. doi: 10.1128/JVI.00039-15. Epub 2015 May 20.

28.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.

Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF.

Nat Biotechnol. 2015 May;33(5):549-554. doi: 10.1038/nbt.3179. Epub 2015 Mar 23.

29.

Hepatitis C virus infection of cholangiocarcinoma cell lines.

Fletcher NF, Humphreys E, Jennings E, Osburn W, Lissauer S, Wilson GK, van IJzendoorn SC, Baumert TF, Balfe P, Afford S, McKeating JA.

J Gen Virol. 2015 Jun;96(Pt 6):1380-8. doi: 10.1099/vir.0.000090. Epub 2015 Feb 20. Review.

30.

Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection.

Wilson GK, Farquhar MJ, Meredith L, Dhawan A, Mitry R, Balfe P, McKeating JA.

J Gen Virol. 2015 Jun;96(Pt 6):1369-73. doi: 10.1099/vir.0.000085. Epub 2015 Feb 9.

31.

Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.

Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA, Krey T.

J Virol. 2015 Feb;89(4):2170-81. doi: 10.1128/JVI.02190-14. Epub 2014 Dec 3.

32.

Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions.

Wilson GK, Tennant DA, McKeating JA.

J Hepatol. 2014 Dec;61(6):1397-406. doi: 10.1016/j.jhep.2014.08.025. Epub 2014 Aug 23. Review.

33.

Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.

Meredith LW, Farquhar MJ, Tarr AW, McKeating JA.

Hepatology. 2014 Dec;60(6):1891-901. doi: 10.1002/hep.27333. Epub 2014 Oct 27.

34.

A role for CD81 and hepatitis C virus in hepatoma mobility.

Brimacombe CL, Wilson GK, Hübscher SG, McKeating JA, Farquhar MJ.

Viruses. 2014 Mar 24;6(3):1454-72. doi: 10.3390/v6031454.

35.

IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria.

Hwang KK, Trama AM, Kozink DM, Chen X, Wiehe K, Cooper AJ, Xia SM, Wang M, Marshall DJ, Whitesides J, Alam M, Tomaras GD, Allen SL, Rai KR, McKeating J, Catera R, Yan XJ, Chu CC, Kelsoe G, Liao HX, Chiorazzi N, Haynes BF.

PLoS One. 2014 Mar 10;9(3):e90725. doi: 10.1371/journal.pone.0090725. eCollection 2014.

36.

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, Verhoye L, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux-Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A.

J Virol. 2014 May;88(10):5502-10. doi: 10.1128/JVI.03574-13. Epub 2014 Mar 5.

37.

The past, present and future of neutralizing antibodies for hepatitis C virus.

Ball JK, Tarr AW, McKeating JA.

Antiviral Res. 2014 May;105:100-11. doi: 10.1016/j.antiviral.2014.02.013. Epub 2014 Feb 26. Review.

38.

Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation.

Colley HE, Hearnden V, Avila-Olias M, Cecchin D, Canton I, Madsen J, MacNeil S, Warren N, Hu K, McKeating JA, Armes SP, Murdoch C, Thornhill MH, Battaglia G.

Mol Pharm. 2014 Apr 7;11(4):1176-88. doi: 10.1021/mp400610b. Epub 2014 Mar 17.

39.

Editorial overview - virus entry: towards reality - refining models of virus entry.

Marsh M, McKeating JA.

Curr Opin Virol. 2014 Feb;4:v-vi. doi: 10.1016/j.coviro.2014.01.001. Epub 2014 Jan 31. No abstract available.

PMID:
24491833
40.

Entry of hepatitis B and C viruses - recent progress and future impact.

Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA, Urban S.

Curr Opin Virol. 2014 Feb;4:58-65. doi: 10.1016/j.coviro.2013.12.002. Epub 2014 Jan 14. Review.

PMID:
24418809
41.

Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner.

Fletcher NF, Sutaria R, Jo J, Barnes A, Blahova M, Meredith LW, Cosset FL, Curbishley SM, Adams DH, Bertoletti A, McKeating JA.

Hepatology. 2014 Apr;59(4):1320-30. doi: 10.1002/hep.26911. Epub 2014 Feb 25.

42.

Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission.

Meredith LW, Zitzmann N, McKeating JA.

Antiviral Res. 2013 Dec;100(3):636-9. doi: 10.1016/j.antiviral.2013.10.006. Epub 2013 Oct 21.

43.

Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies.

Fofana I, Zona L, Thumann C, Heydmann L, Durand SC, Lupberger J, Blum HE, Pessaux P, Gondeau C, Reynolds GM, McKeating JA, Grunert F, Thompson J, Zeisel MB, Baumert TF.

J Virol. 2013 Sep;87(18):10405-10. doi: 10.1128/JVI.01691-13. Epub 2013 Jul 17.

44.

Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication.

Rowe IA, Galsinh SK, Wilson GK, Parker R, Durant S, Lazar C, Branza-Nichita N, Bicknell R, Adams DH, Balfe P, McKeating JA.

Hepatology. 2014 Feb;59(2):375-84. doi: 10.1002/hep.26571. Epub 2013 Dec 18.

45.

Production, purification and characterization of recombinant, full-length human claudin-1.

Bonander N, Jamshad M, Oberthür D, Clare M, Barwell J, Hu K, Farquhar MJ, Stamataki Z, Harris HJ, Dierks K, Dafforn TR, Betzel C, McKeating JA, Bill RM.

PLoS One. 2013 May 21;8(5):e64517. doi: 10.1371/journal.pone.0064517. Print 2013.

46.

An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.

Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T.

Hepatology. 2013 Sep;58(3):932-9. doi: 10.1002/hep.26430. Epub 2013 Jul 30.

PMID:
23553604
47.

HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex.

Zona L, Lupberger J, Sidahmed-Adrar N, Thumann C, Harris HJ, Barnes A, Florentin J, Tawar RG, Xiao F, Turek M, Durand SC, Duong FH, Heim MH, Cosset FL, Hirsch I, Samuel D, Brino L, Zeisel MB, Le Naour F, McKeating JA, Baumert TF.

Cell Host Microbe. 2013 Mar 13;13(3):302-13. doi: 10.1016/j.chom.2013.02.006.

48.

A bile acid transporter as a candidate receptor for hepatitis B and D virus entry.

Xiao F, McKeating JA, Baumert TF.

J Hepatol. 2013 Jun;58(6):1246-8. doi: 10.1016/j.jhep.2013.01.036. Epub 2013 Feb 8. No abstract available.

49.

Early infection events highlight the limited transmissibility of hepatitis C virus in vitro.

Meredith LW, Harris HJ, Wilson GK, Fletcher NF, Balfe P, McKeating JA.

J Hepatol. 2013 Jun;58(6):1074-80. doi: 10.1016/j.jhep.2013.01.019. Epub 2013 Jan 23.

PMID:
23353869
50.

Hepatoma polarization limits CD81 and hepatitis C virus dynamics.

Harris HJ, Clerte C, Farquhar MJ, Goodall M, Hu K, Rassam P, Dosset P, Wilson GK, Balfe P, Ijzendoorn SC, Milhiet PE, McKeating JA.

Cell Microbiol. 2013 Mar;15(3):430-45. doi: 10.1111/cmi.12047. Epub 2012 Nov 20.

Supplemental Content

Loading ...
Support Center